QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
Free Trial
NASDAQ:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free TRIL Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$18.44
▼
$18.44
50-Day Range
$17.50
▼
$18.44
52-Week Range
$5.80
▼
$20.96
Volume
8 shs
Average Volume
1.87 million shs
Market Capitalization
$1.94 billion
P/E Ratio
29.74
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
TRIL stock logo

About Trillium Therapeutics Stock (NASDAQ:TRIL)

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

TRIL Stock News Headlines

November 10, 2023 | businesswire.com
Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com
November 8, 2023 | benzinga.com
Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
July 31, 2023 | uk.finance.yahoo.com
The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period
April 26, 2023 | msn.com
WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'
April 4, 2023 | uk.finance.yahoo.com
Leukemia Therapeutics Global Market Report 2023
March 28, 2023 | finance.yahoo.com
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
October 19, 2022 | nz.finance.yahoo.com
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
April 16, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
September 14, 2022 | seekingalpha.com
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
September 12, 2022 | nz.finance.yahoo.com
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
August 17, 2022 | seekingalpha.com
Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed
June 22, 2022 | markets.businessinsider.com
10 Psychedelics CEOs To Pay Attention To In 2022
May 20, 2022 | edition.cnn.com
Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?
March 20, 2022 | nasdaq.com
3 Dividend Stocks That We'd Buy Without Any Hesitation
March 17, 2022 | stockhouse.com
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders
February 17, 2022 | finanznachrichten.de
NeonMind Biosciences Inc.: NeonMind to Open its Inaugural Specialty Mental Health Clinic in Mississauga, Ontario
December 14, 2021 | au.finance.yahoo.com
CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035 - ResearchAndMarkets.com
December 14, 2021 | law360.com
3 Firms Draw Up Pfizer's $6.7B Arena Pharmaceuticals Buy
October 25, 2021 | finance.yahoo.com
Is Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?
October 16, 2021 | msn.com
2 Top Healthcare Stocks That Could Be Bought Out in 2022
October 13, 2021 | msn.com
BRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14
September 22, 2021 | finance.yahoo.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GWB, KDMN, SIC, TRIL; Shareholders are Encouraged to Contact the Firm
September 11, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Trillium Therapeutics, Inc. - TRIL
September 9, 2021 | benzinga.com
Moore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law Firm
September 7, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Reminds DSPG, ADTN, TRIL, and SIC Shareholders About Its Ongoing Investigations
September 4, 2021 | finance.yahoo.com
Why Investors Should Love Pfizer's Acquisition of Trillium
See More Headlines
Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/18/2021
Today
4/16/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRIL
CUSIP
N/A
CIK
1616212
Web
www.trilliumtherapeutics.com
Phone
(416) 595-0627
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$0.62
Trailing P/E Ratio
29.74
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-59,350,000.00
Net Margins
N/A
Pretax Margin
-113,720.92%
Return on Equity
-23.31%
Return on Assets
-18.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.82
Quick Ratio
19.82

Sales & Book Value

Annual Sales
$150,000.00
Price / Sales
12,907.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.56 per share
Price / Book
7.20

Miscellaneous

Outstanding Shares
104,995,000
Free Float
95,440,000
Market Cap
$1.94 billion
Optionable
Optionable
Beta
2.08
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Jan Skvarka
    President, Chief Executive Officer & Director
  • James T. Parsons
    Chief Financial Officer
  • Robert A. UgerRobert A. Uger
    Chief Scientific Officer
  • Kathleen Large
    Senior Vice President-Clinical Operations
  • Ingmar Bruns
    Chief Medical Officer

Key Competitors

View All Competitors

TRIL Stock Analysis - Frequently Asked Questions

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) announced its earnings results on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01.

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

This page (NASDAQ:TRIL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends